Preclinical News and Research

RSS

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Researchers developed a first-of-its-kind microbicide gel formulation that shows promise for safe vaginal and rectal administration to prevent the sexual transmission of human immunodeficiency virus (HIV).

15 Nov 2013

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Cancer can be treated by a number of different ways depending on the location, grade and stage of tumour. A patient's age, medical history and lifestyle will also be taken into consideration and a combination of treatments will also be adopted to provide maximum effect.

14 Nov 2013

Mount Sinai researchers successfully test SUMO-1 gene therapy to reverse heart failure

Researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai have successfully tested a powerful gene therapy, delivered directly into the heart, to reverse heart failure in large animal models.

14 Nov 2013

Neovasc's Tiara transcatheter mitral valve replacement technology gets US patent

Neovasc Inc. today announced that the first patent covering the company's innovative Tiara transcatheter mitral valve replacement technology has been issued by the US Patent and Trademark Office.

13 Nov 2013

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Merck Serono, the biopharmaceutical division of Merck, today announced that a global licensing, co-development, and commercialization agreement for BeiGene-290 has been signed with BeiGene Co., Ltd., a biotech research and development company in Beijing, China.

13 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Lower amounts of brown adipose tissue (BAT, or ‘brown fat’) could help explain why south Asians—who make up a fifth of the world’s population—have an exceptionally high susceptibility to developing metabolic problems such as obesity and type 2 diabetes.

13 Nov 2013

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Revalesio Corporation is pleased to announce a new collaboration with noted neurologist Dr. Roland Martin, Head of Neuroimmunology and MS Research at the Department of Neurology, University Hospital Zurich. Dr. Martin will be conducting a Phase IIa clinical trial of RNS60 in patients with relapsing-remitting multiple sclerosis.

12 Nov 2013

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Swiss-based Helsinn group has granted Chugai Pharma Marketing Ltd., a wholly-owned subsidiary of Chugai Pharmaceutical Co., Ltd., exclusive commercialization rights to their innovative ghrelin receptor agonist, anamorelin, for the three major European pharma markets.

12 Nov 2013

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced top-line results from two Phase 2 clinical studies of Z160 in chronic pain indications.

11 Nov 2013

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

IVIG is a hugely successful biological with FDA approval for treating idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barré syndrome, Graves ophthalmopathy and numerous polyneuropathies.

11 Nov 2013

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

NanoViricides, Inc. announced today that the European Medicines Agency, has awarded orphan drug designation to DengueCide, the Company's drug candidate for the treatment of dengue and dengue hemorrhagic fever.

11 Nov 2013

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

Patrys Limited, a clinical stage biotechnology company has today announced that it is initiating an investigator-sponsored trial evaluating the effectiveness of Patrys’ lead anti-cancer drug PAT-SM6 in combination with carfilzomib, in patients with relapsed and refractory multiple myeloma.

11 Nov 2013

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

GW Pharmaceuticals plc a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme.

11 Nov 2013

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

BioInvent International AB today announces that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.

11 Nov 2013

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Researchers have launched an early-stage clinical trial of an investigational vaccine designed to prevent genital herpes disease. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the Phase I trial, which is being conducted at the NIH Clinical Center in Bethesda, Md.

11 Nov 2013

Patrys gets second US patent for anti-cancer product PAT-LM1

Patrys Limited, a clinical stage biotechnology company is pleased to advise that it has been granted a second US patent for lead anti-cancer product PAT-LM1.

8 Nov 2013

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

BioCryst Pharmaceuticals, Inc. today announced that it has dosed the first subject in OPuS-1 (Oral ProphylaxiS-1), a Phase 2a proof of concept clinical trial of orally-administered BCX4161 in patients with hereditary angioedema.

8 Nov 2013

New drug combination therapy effectively kills cancer cells

Results from a recent preclinical study have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.

6 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

Preclinical News and Research

New microbicide gel formulation shows promise for safe vaginal and rectal administration to prevent HIV

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Mount Sinai researchers successfully test SUMO-1 gene therapy to reverse heart failure

Neovasc's Tiara transcatheter mitral valve replacement technology gets US patent

Merck Serono signs co-development and commercialization agreement for BeiGene-290

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Study explains why south Asians have high susceptibility to developing type 2 diabetes

Revalesio to conduct RNS60 Phase IIa clinical trial in RRMS patients

Helsinn grants exclusive commercialization rights to Chugai Pharma Marketing for anamorelin drug

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Generating an alternative to IVIG therapy: an interview with Professor Richard Pleass, LSTM

European Medicines Agency awards orphan drug designation to NanoViricides' DengueCide

Patrys initiates IST of PAT-SM6 in combination with carfilzomib in multiple myeloma patients

GW Pharmaceuticals starts Phase 1b/2a clinical trial for Recurrent Glioblastoma Multiforme

BioInvent International receives US patent for drug discovery technology F.I.R.S.T.

Researchers launch clinical trial of investigational vaccine designed to prevent genital herpes disease

Patrys gets second US patent for anti-cancer product PAT-LM1

BioCryst Pharmaceuticals initiates BCX4161 Phase 2a trial in HAE patients

New drug combination therapy effectively kills cancer cells

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics